Active, not recruitingPhase 2NCT04485949
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Studying Glioblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Imvax
- Intervention
- IGV-001 Cell Immunotherapy(combination_product)
- Enrollment
- 93 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2023 – 2027
Study locations (23)
- Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- Henry Ford Health System, Detroit, Michigan, United States
- Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
- John Theurer Cancer Center At Hackensack UMC, Hackensack, New Jersey, United States
- Jersey Shore University Medical Center, Neptune City, New Jersey, United States
- Northwell Health at North Shore University Hospital, Manhasset, New York, United States
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Columbia University Medical Center, New York, New York, United States
- Weill Cornell Medicine, New York, New York, United States
- Lenox Hill Hospital, New York, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- Westchester Medical Center, Valhalla, New York, United States
- University of North Carolina (UNC) - Chapel Hill, Chapel Hill, North Carolina, United States
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04485949 on ClinicalTrials.govOther trials for Glioblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07501559A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)Jecho Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE2NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIBlack Diamond Therapeutics, Inc.
- RECRUITINGPHASE1NCT07464925A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade GliomaTetragon Biosciences Ltd
- RECRUITINGNCT07411690Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial TumorsMedical University of Warsaw
- RECRUITINGPHASE1NCT07480941Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaBeijing Biotech
- RECRUITINGPHASE2NCT07225621Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed GlioblastomaAlpheus Medical, Inc.
- RECRUITINGPHASE1, PHASE2NCT073912155G-PEARL: Paxalisib in Malignant Brain TumoursInstitute of Cancer Research, United Kingdom
- RECRUITINGNANCT07426848OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour PatientsRoyal College of Surgeons, Ireland